Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies
Authors:
Open Access
- 20 March 2021
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (3) , 426-438
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Janssen Research and Development
This publication has 29 references indexed in Scilit:
- Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useBlood, 2016
- Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional studyThe Lancet Haematology, 2016
- Heavy menstrual bleeding on rivaroxabanBritish Journal of Haematology, 2015
- Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2014
- Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolismCurrent Medical Research and Opinion, 2014
- Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysisThrombosis Research, 2013
- Case Report: Dabigatran-Associated Gynecologic BleedingHospital Pharmacy, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Venous thromboembolism: Epidemiology and magnitude of the problemBest Practice & Research Clinical Haematology, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012